What’s the current market cap for Valneva SE stock?

Valneva SE (VLA) has a market cap of €435m as of June 17, 2026.

What is the P/E ratio for Valneva SE stock?

The price to earnings (P/E) ratio for Valneva SE (VLA) stock is 0 as of June 17, 2026.

Does Valneva SE stock pay dividends?

No, Valneva SE (VLA) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Valneva SE dividend payment date?

Valneva SE (VLA) stock does not pay dividends to its shareholders.

What is the beta indicator for Valneva SE?

Valneva SE (VLA) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Valneva SE stock | €VLA Share Price

05:30

09:10

12:45

16:25

20:00

About Valneva SE

Valneva SE is a biotechnology company specializing in the development and commercialization of vaccines for infectious diseases. The company's portfolio includes vaccines for diseases such as Japanese encephalitis and cholera. Valneva is actively engaged in developing vaccines for Lyme disease and chikungunya. Founded in 2013 through the merger of Intercell AG and Vivalis, Valneva is headquartered in Saint-Herblain, France. The company operates primarily in Europe but has a global reach through various strategic partnerships and licensing agreements. Valneva's competitive strength lies in its focus on addressing unmet medical needs with its diverse pipeline of innovative vaccine candidates.

Ticker

€VLA

Sector

Health

Primary listing

PAR

Employees

674

Headquarters

Saint-Herblain, France

Website

valneva.com

Valneva SE Metrics

BasicAdvanced

€435m

-€0.79

1.40

Bulls say / Bears say

Topline results from the Phase 3 VALOR trial showed the Lyme disease vaccine candidate PF-07307405 (formerly VLA15) achieved over 70% efficacy in preventing Lyme disease in individuals aged ≥5, bolstering plans for regulatory submissions. (Pfizer Business Wire)

In early May 2026, the Brazilian Health Regulatory Agency (ANVISA) authorized Instituto Butantan to locally manufacture Valneva’s single-dose chikungunya vaccine IXCHIQ®, facilitating scale-up in a major endemic market. (Nasdaq)

Valneva’s VLA15 Lyme disease vaccine candidate reported positive final Phase 2 immunogenicity and safety data on November 26, 2025, demonstrating strong antibody responses across all six serotypes and no safety concerns six months post-booster. (Valneva SE)

The Company voluntarily withdrew its U.S. biologics license application (BLA) and Investigational New Drug (IND) application for the single-dose chikungunya vaccine IXCHIQ® after the FDA suspended its U.S. license, delaying any potential U.S. market entry. (Nasdaq)

Valneva reported a net loss of €32.1 million in Q1 2026, widening from a €9.2 million loss a year earlier, driven primarily by lower product sales volumes and the strategic wind-down of third-party distribution. (MarketScreener)

On May 13, 2026, Valneva cut its 2026 product sales guidance to €135 million–€150 million from €145 million–€160 million, citing emerging unfavorable trends in travel-vaccine uptake across core markets due to geopolitical factors. (Reuters via Boursorama)

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Market data provided by CBOE Europe and Deutsche Börse.

Buy €VLA

€

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Data summarised monthly by Lightyear AI. Last updated on 23 May 2026.

About Valneva SE

Ticker

Primary listing

Employees

Valneva SE Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €VLA

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Valneva SE/€VLA

About Valneva SE

Ticker

Primary listing

Employees

Valneva SE Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy €VLA

Upcoming events

No upcoming events

What’s the current market cap for Valneva SE stock?

What is the P/E ratio for Valneva SE stock?

Does Valneva SE stock pay dividends?

When is the next Valneva SE dividend payment date?

What is the beta indicator for Valneva SE?

Bulls say / Bears say